β-elemene blocks lipid-induced inflammatory pathways via PPARβ activation in heart failure

Eur J Pharmacol. 2021 Nov 5:910:174450. doi: 10.1016/j.ejphar.2021.174450. Epub 2021 Aug 26.

Abstract

This study aims to investigate the effects of β-elemene on a mouse model of heart failure (HF) and to elucidate the underlying mechanisms in vitro approaches. In this study, left anterior descending (LAD)-induced HF mouse model and oxygen-glucose deprivation/recovery (OGD/R)-induced H9C2 model were leveraged to assess the therapeutic effects of β-elemene. Histological examination, western blot and quantitative real-time PCR analysis (RT-qPCR) and immunofluorescence staining was utilized to elucidate mechanism of β-elemene in lipid-induced inflammation. Results showed that β-elemene improved heart function in HF mice evidenced by the increase of cardiac ejection fraction (EF) and fractional shortening (FS) values. Furthermore, β-elemene administration rescued ventricular dilation, lipid accumulation, and inflammatory infiltration in arginal areas of mice myocardial infarction. At transcription level, β-elemene augmented the mRNA expression of fatty acid oxidation-associated genes, such as peroxisome proliferator-activated receptor-β (PPARβ). In vitro, treatment of β-elemene increased carnitine palmitoyltransferase 1A (CPT1A) and sirtuin 3 (SIRT3). Hallmarks of inflammation including the nuclear translocation of nuclear factor κB (NF-κB) and the degradation of inhibitory κBα (IκBα) were significantly suppressed. Consistently, we observed down-regulation of interleukin-6 (IL-6) and pro-inflammatory cytokines (such as TNFα) in β-elemene treated H9C2 cells. Finally, molecular docking model predicted an interaction between β-elemene and PPARβ protein. Furthermore, β-elemene increased the expression of PPARβ, which was validated by antagonist of PPARβ and siRNA for PPARβ.

Keywords: Heart failure; Inflammation; Lipid accumulation; PPARβ; β-elemene.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / pharmacology*
  • Anti-Inflammatory Agents / therapeutic use
  • Cardiotonic Agents / pharmacology*
  • Cardiotonic Agents / therapeutic use
  • Cell Line
  • Cell Survival / drug effects
  • Disease Models, Animal
  • Endoribonucleases / metabolism
  • Heart Failure / chemically induced
  • Heart Failure / metabolism*
  • Heart Failure / pathology
  • Heart Failure / prevention & control*
  • Inflammation / chemically induced
  • Inflammation / metabolism*
  • Lipids / toxicity
  • Male
  • Mice
  • Mitochondria / drug effects
  • Molecular Docking Simulation
  • Multienzyme Complexes / metabolism
  • NF-KappaB Inhibitor alpha / metabolism
  • NF-kappa B / metabolism
  • PPAR-beta / agonists*
  • PPAR-beta / chemistry
  • PPAR-beta / genetics
  • PPAR-beta / metabolism
  • Protein Serine-Threonine Kinases / metabolism
  • Rats
  • Sesquiterpenes / chemistry
  • Sesquiterpenes / pharmacology*
  • Sesquiterpenes / therapeutic use

Substances

  • Anti-Inflammatory Agents
  • Cardiotonic Agents
  • Ern1 protein, rat
  • Lipids
  • Multienzyme Complexes
  • NF-kappa B
  • PPAR-beta
  • Sesquiterpenes
  • beta-elemene
  • NF-KappaB Inhibitor alpha
  • Protein Serine-Threonine Kinases
  • Endoribonucleases